

Supplemental Material to:

Markus Knuf, Yaela Baine, Veronique Bianco, Dominique Boutriau and Jacqueline M. Miller. Antibody persistence and immune memory 15 mo after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (menacwy-TT) in toddlers and young children. *Human Vaccines & Immunotherapeutics* 2012; 8(7); <http://dx.doi.org/10.4161/hv.20229>
<http://www.landesbioscience.com/journals/vaccines/article/20229/>

Supplementary Table 2. Adjusted GMT ratios between groups for serogroups A, C, W-135, and Y at 15 months after the primary dose (ATP cohort for persistence) and at one month

| Serogroup | Age group | ACWY-TT group | | Control group | | GMT ratio (95% CI) (ACWY-TT / Control) | | |
|--|-----------|---------------|--------------|---------------|--------------|---|-------|-------|
| | | N | Adjusted GMT | N | Adjusted GMT | Value | LL | UL |
| 15 months after the primary dose | | | | | | | | |
| A | Toddlers | 37 | 527.0 | 33 | 15.4 | 34.31 | 15.18 | 77.58 |
| | Children | 38 | 950.6 | 24 | 257.8 | 3.69 | 2.04 | 6.67 |
| C | Toddlers | 38 | 171.9 | 38 | 27.0 | 6.37 | 2.86 | 14.20 |
| | Children | 44 | 183.4 | 30 | 26.8 | 6.85 | 3.26 | 14.41 |
| W-135 | Toddlers | 28 | 661.0 | 31 | 15.9 | 41.62 | 19.36 | 89.48 |
| | Children | 31 | 1710.9 | 19 | 401.2 | 4.26 | 2.27 | 8.00 |
| Y | Toddlers | 38 | 409.5 | 38 | 73.2 | 5.59 | 2.79 | 11.21 |
| | Children | 45 | 1206.5 | 32 | 174.3 | 6.92 | 3.80 | 12.59 |
| one month after the polysaccharide challenge dose | | | | | | | | |
| A | Toddlers | 23 | 3246.0 | 28 | 529.9 | 6.13 | 3.47 | 10.80 |
| C | Toddlers | 31 | 6094.2 | 29 | 5264.0 | 1.16 | 0.66 | 2.04 |
| W-135 | Toddlers | 22 | 9675.6 | 22 | 1439.2 | 6.72 | 3.78 | 11.97 |
| Y | Toddlers | 30 | 5840.6 | 29 | 521.8 | 11.19 | 6.13 | 20.44 |

after the polysaccharide challenge dose (ATP cohort for immune memory)

Footnote: Toddlers= participants 12–14 months of age at the time of the primary vaccination

Children= participants 3–5 years of age at the time of the primary vaccination

ACWY-TT = participants primed with MenACWY-TT

Control= participants primed with MenC-CRM₁₉₇ in the toddlers age stratum or with MenPS in the children age stratum

N= number of participants with available results

Adjusted GMT= geometric mean antibody titre adjusted for baseline titre

95% CI= exact 95% confidence interval

LL= lower limit; UL= upper limit